Literature DB >> 19145096

Fatal herpes simplex virus hepatitis in a patient with esophageal cancer under radiochemotherapy.

Birgit Grimm1, Barbara Padberg, Thomas Ruhstaller, Felix Fleisch, Roger von Moos.   

Abstract

BACKGROUND: Herpes simplex virus (HSV) infections are frequent. However, HSV hepatitis is rare and may lead to a life-threatening condition. CASE REPORT: A 68-year-old patient with a locally advanced and inoperable esophageal carcinoma was treated with induction chemotherapy and combined chemoradiation. After a total of 9 weeks of treatment, he developed fulminant liver failure of unknown origin and died a few days later. Surprisingly, the post mortem examination revealed an HSV infection of the esophagus and an HSV-associated necrotisizing hepatitis.
CONCLUSION: In this immunocompromised patient, we postulate an HSV-associated esophagitis that led to viremia and fulminant hepatitis. Especially in immunocompromised hosts, HSV hepatitis should be considered in the differential diagnosis in patients with anicteric hepatitis and marked elevation of transaminases. A liver biopsy is the quickest and most definitive diagnostic tool to diagnose HSV hepatitis. If this is not possible because of severe coagulopathy, polymerase chain reaction for HSV DNA should be performed. Awaiting diagnosis, a prompt empirical treatment with acyclovir has to be discussed in case of a characteristic biochemical profile.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19145096     DOI: 10.1159/000162283

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  2 in total

1.  Fatal herpes simplex virus hepatitis following neoadjuvant chemoradiotherapy and anterior resection for rectal cancer.

Authors:  D P Toomey; A S Dhadda; L A Sanni; J P Cooke; J E Hartley
Journal:  Ann R Coll Surg Engl       Date:  2014-11       Impact factor: 1.891

Review 2.  The roles of viruses in brain tumor initiation and oncomodulation.

Authors:  Alexander Kofman; Lucasz Marcinkiewicz; Evan Dupart; Anton Lyshchev; Boris Martynov; Anatolii Ryndin; Elena Kotelevskaya; Jay Brown; David Schiff; Roger Abounader
Journal:  J Neurooncol       Date:  2011-07-01       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.